Stock Code: 002653.SZ
Home
News
Innovation
Pipeline R&D Platforms
Products
Product List Product Topics Pharmacovigilance
Investors
Stock Information Public Announcements Market Data Q&A Investor Hotline
Join Us
Talent Philosophy Careers
About Haisco
About Us Business Presence
Contact Us

EN

CN EN

EN

CN EN
Stock code: 002653.SZ

Stock code: 002653.SZ

Home
News
Innovation
Pipeline R&D Platforms
Products
Product List Product Topics Pharmacovigilance
Investors
Stock Information Company Announcements Market Data Q&A Investor Hotline
Join Us
Talent Philosophy Careers
About Haisco
About Us Business Presence
Contact Us
GLOBAL
English China

Back

One picture to understand | Haisco Co. releases 2026 semi-annual performance report

海思科发布2026半年度业绩(1).webp

Back to list

News Center

Learn more
Xinhua Net: Class 1 innovative drug Youkepan is approved for Phase 7 of Nanjing’s “Ninghui Bao”, accelerating benefits for PNH patients
Business News

Xinhua Net: Class 1 innovative drug Youkepan is approved for Phase 7 of Nanjing’s “Ninghui Bao”, accelerating benefits for PNH patients

2026-09-24

Learn more
Haisco Co. launches the 2026 China Fair Competition Policy Promotion Week activity
Business News

Haisco Co. launches the 2026 China Fair Competition Policy Promotion Week activity

2026-09-11

Learn more
Haisco's independently developed pre-clinical autoimmune innovation drug has received an exclusive overseas license, with potential value exceeding $1.5 billion.
Business News

Haisco's independently developed pre-clinical autoimmune innovation drug has received an exclusive overseas license, with potential value exceeding $1.5 billion.

2026-08-26

Learn more

Haisco Group's Official WeChat Account

Haisco Investor Relations WeChat Account

Haisco Raw Materials Procurement Inquiries

News
Innovation
Pipeline R&D Platforms
Products
Product List Product Topics Pharmacovigilance
Investors
Stock Information Public Announcements Market Data Q&A Investor Hotline
Join Us
Talent Philosophy Careers
About Haisco
About Us Business Presence
Contact Us

Contact Number

+86-028-67250666 (Corporate Services) +86-028-67250620 (Business Development and Cooperation Division) +86-028-67250551 (Investor Hotline)

COPYRIGHT 2026 @ HAISCO Pharmaceutical Group Co., Ltd.

Zang ICP Registration No. 20000012-1 Shu ICP Registration No. 16033962-2Shu ICP No. 16033962-3 The Tibetan public network security registration number is 54222102000053.(Tibetan)-Non-operational-2019-0003

Pharmacovigilance Statement Privacy